Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban

B. Pina-Beltran, D. Dimitrov, N. McKay, M. Giot, Z. Zdráhal, D. Potěšil, V. Pustka, J. Peinado-Izaguerri, J. Saez-Rodriguez, S. Poitevin, S. Burtey

. 2025 ; 15 (1) : 6075. [pub] 20250219

Language English Country England, Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25009846

Grant support
860329 Marie-Curie ITN "STRATEGY-CKD European Union's Horizon 2020 research and innovation program
0000432 EU Horizon 2020 program Epic-XS

Chronic Kidney Disease (CKD) is associated with heightened risk of thrombosis. Prescription of anticoagulants is key to manage it; however, CKD patients have shown an increased risk of bleeding under anticoagulation therapy compared to non-CKD patients. We hypothesized that the sex could modify the metabolism of indoxyl sulfate (IS), a uremic toxin and Apixaban. Our intoxication model shows that higher doses of IS and apixaban accumulate in the plasma of female mice because of expression differences in efflux transporters and cytochromes in the liver, ileum and kidneys, when compared to males. Furthermore, we found that accumulation of apixaban in females contributes to increased bleeding. Transcriptional analysis of liver samples revealed elevated Sult1a1 but reduced Abcg2 and Cyp3a11 in female mice, while in the kidneys the expression rates of Oat1 and Oat3 were respectively lower and higher than those observed in males, potentially affecting drug clearance. Whole proteomics liver analysis confirmed the previous transcriptional results at the protein level and revealed that sex had a major influence in regulating both coagulation and drug metabolism pathways. Thus, our findings underline the need for inclusive clinical and preclinical trials to accurately reflect sex-specific metabolic variations, and to consider CKD-specific changes to optimize dosing, minimize side effects, and improve patient outcomes.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009846
003      
CZ-PrNML
005      
20250429135314.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-025-90405-5 $2 doi
035    __
$a (PubMed)39972038
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Pina-Beltran, Blanca $u Faculté de pharmacie, Aix Marseille Univ, INSERM, INRAE, C2VN, Bd Jean Moulin, Marseille, 13005, France
245    10
$a Unveiling the role of sex in the metabolism of indoxyl sulfate and apixaban / $c B. Pina-Beltran, D. Dimitrov, N. McKay, M. Giot, Z. Zdráhal, D. Potěšil, V. Pustka, J. Peinado-Izaguerri, J. Saez-Rodriguez, S. Poitevin, S. Burtey
520    9_
$a Chronic Kidney Disease (CKD) is associated with heightened risk of thrombosis. Prescription of anticoagulants is key to manage it; however, CKD patients have shown an increased risk of bleeding under anticoagulation therapy compared to non-CKD patients. We hypothesized that the sex could modify the metabolism of indoxyl sulfate (IS), a uremic toxin and Apixaban. Our intoxication model shows that higher doses of IS and apixaban accumulate in the plasma of female mice because of expression differences in efflux transporters and cytochromes in the liver, ileum and kidneys, when compared to males. Furthermore, we found that accumulation of apixaban in females contributes to increased bleeding. Transcriptional analysis of liver samples revealed elevated Sult1a1 but reduced Abcg2 and Cyp3a11 in female mice, while in the kidneys the expression rates of Oat1 and Oat3 were respectively lower and higher than those observed in males, potentially affecting drug clearance. Whole proteomics liver analysis confirmed the previous transcriptional results at the protein level and revealed that sex had a major influence in regulating both coagulation and drug metabolism pathways. Thus, our findings underline the need for inclusive clinical and preclinical trials to accurately reflect sex-specific metabolic variations, and to consider CKD-specific changes to optimize dosing, minimize side effects, and improve patient outcomes.
650    _2
$a zvířata $7 D000818
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    12
$a pyrazoly $x farmakologie $7 D011720
650    12
$a indican $x metabolismus $x krev $7 D007200
650    _2
$a myši $7 D051379
650    12
$a pyridony $x aplikace a dávkování $x metabolismus $x farmakologie $7 D011728
650    12
$a játra $x metabolismus $x účinky léků $7 D008099
650    _2
$a ledviny $x metabolismus $x účinky léků $7 D007668
650    _2
$a sexuální faktory $7 D012737
650    _2
$a ABC transportér z rodiny G, člen 2 $x metabolismus $x genetika $7 D000070997
650    _2
$a antikoagulancia $x aplikace a dávkování $x metabolismus $7 D000925
650    _2
$a chronická renální insuficience $x metabolismus $x farmakoterapie $7 D051436
650    _2
$a protein 1 přenášející organické anionty $x metabolismus $x genetika $7 D027362
650    _2
$a přenašeče organických aniontů nezávislé na sodíku $x metabolismus $x genetika $7 D029362
650    _2
$a krvácení $x metabolismus $7 D006470
650    _2
$a cytochrom P-450 CYP3A $x metabolismus $x genetika $7 D051544
650    _2
$a myši inbrední C57BL $7 D008810
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dimitrov, Daniel $u Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg University, BioQuant, Heidelberg, Germany
700    1_
$a McKay, Nathalie $u Faculté de pharmacie, Aix Marseille Univ, INSERM, INRAE, C2VN, Bd Jean Moulin, Marseille, 13005, France
700    1_
$a Giot, Matthieu $u Centre de Néphrologie, Medipole Saint-Roch, Cabestany, France
700    1_
$a Zdráhal, Zbyněk $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic $u National Centre for Biomolecular Research, Masaryk University, Brno, Czech Republic
700    1_
$a Potěšil, David $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Pustka, Václav $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic
700    1_
$a Peinado-Izaguerri, Jorge $u School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK
700    1_
$a Saez-Rodriguez, Julio $u Faculty of Medicine, and Heidelberg University Hospital, Institute for Computational Biomedicine, Heidelberg University, BioQuant, Heidelberg, Germany $u European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Hinxton, Cambridgeshire, UK
700    1_
$a Poitevin, Stéphane $u Faculté de pharmacie, Aix Marseille Univ, INSERM, INRAE, C2VN, Bd Jean Moulin, Marseille, 13005, France
700    1_
$a Burtey, Stéphane $u Faculté de pharmacie, Aix Marseille Univ, INSERM, INRAE, C2VN, Bd Jean Moulin, Marseille, 13005, France. stephane.burtey@univ-amu.fr $u Centre de Néphrologie et Transplantation Rénale, Aix Marseille Univ, AP-HM Hôpital de la Conception, Marseille, France. stephane.burtey@univ-amu.fr
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 15, č. 1 (2025), s. 6075
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39972038 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135309 $b ABA008
999    __
$a ok $b bmc $g 2311311 $s 1246927
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 15 $c 1 $d 6075 $e 20250219 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a 860329 Marie-Curie ITN "STRATEGY-CKD $p European Union's Horizon 2020 research and innovation program
GRA    __
$a 0000432 $p EU Horizon 2020 program Epic-XS
LZP    __
$a Pubmed-20250415

Find record

Citation metrics

Archiving options